

1 **Acquired equine polyneuropathy of Nordic horses - a conspicuous inclusion body**

2 **Schwannopathy**

3 S. Hanche-Olsen<sup>a,\*</sup>, K. Matiasek<sup>b#</sup>, J. Molín<sup>b</sup>, M. Rosati<sup>b</sup>, C. Hahn<sup>c</sup>, K. Hultin Jäderlund<sup>a</sup>, G.  
4 Gröndahl<sup>d</sup>

5 *<sup>a</sup>Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences,*  
6 *Ullevålsvn 72, 0454 Oslo, Norway. E-mail address: [siv.hanche-olsen@nmbu.no](mailto:siv.hanche-olsen@nmbu.no),*

7 *[karinhultin.jaderlund@nmbu.no](mailto:karinhultin.jaderlund@nmbu.no) <sup>b</sup>Section of Clinical & Comparative Neuropathology, Centre*  
8 *for Clinical Veterinary Medicine, Ludwig-Maximilians-Universität München, Veterinärstr 13,*  
9 *80539 Munich, Germany. E-mail address: [kaspar.matiasek@neuropathologie.de](mailto:kaspar.matiasek@neuropathologie.de),*

10 *[jmolin@unizar.es](mailto:jmolin@unizar.es), [marco.rosati@neuropathologie.de](mailto:marco.rosati@neuropathologie.de). <sup>c</sup>Neuromuscular Disease Laboratory,*

11 *Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush,*

12 *Midlothian EH259RG, UK. E-mail address: [caroline.hahn@ed.ac.uk](mailto:caroline.hahn@ed.ac.uk). <sup>d</sup>Department of Animal*

13 *Health and Microbial Strategies, National Veterinary Institute, 75189 Uppsala, Sweden. E-*

14 *mail address: [gittan.grondahl@sva.se](mailto:gittan.grondahl@sva.se).*

15 *\*Corresponding author for the general part, clinics and epidemiology. Tel.:+4767232388*

16 *#Corresponding author for nerve pathology. Tel.: +498921803313*

17

18 **Abstract**

19 Acquired equine polyneuropathy (AEP), formerly also known as Scandinavian knuckling  
20 syndrome, is one of the most prevalent polyneuropathies in equids in Norway and Sweden,  
21 with more than 400 cases registered since first observations in 1995. Despite geographical  
22 clustering and an association to forage feeding, its aetiology remains unknown. Clinically  
23 AEP is characterized by knuckling due to dysfunction of metatarsophalangeal extensor  
24 muscles. This neuropathological study aimed to gain further insights in the pathobiology of  
25 AEP and its underlying aetiopathogenesis. We thereby confirmed that all affected horses  
26 suffered from similar large fiber neuropathy, exhibiting conspicuous Schwann cell inclusions  
27 in most samples, suggestive of a primary disruption of Schwann cell metabolism leading to  
28 inclusion body schwannopathy with secondary inflammatory changes. The degree of nerve  
29 pathology was not predictive of clinical outcome.

30

31 *Keywords:* Knuckling; schwannopathy; demyelination; inclusion body; inflammatory; nerve  
32 fiber teasing.

33 Abbreviation: Acquired equine polyneuropathy: AEP

## 34 1. Introduction

35 The first case clusters of a unique neuromuscular syndrome in horses characterized by  
36 knuckling in the metatarsophalangeal joints were observed in Norway in 1995 (1) and Sweden  
37 in 1998 (2). Since then, more than 400 cases have been identified throughout Norway,  
38 Sweden and Finland, making this disease the most prevalent polyneuropathy in equids in this  
39 part of the world (3-7). The syndrome was associated ~~with~~ peripheral nerve lesions, but the  
40 cause has not yet been identified. The disease was ~~initially~~~~sometimes~~ referred to as  
41 “Scandinavian knuckling syndrome” ~~in the beginning~~, but is ~~now~~~~lately~~ known as acquired  
42 equine polyneuropathy (AEP).

43 AEP affecteds horses and ponies are of a wide spectrum of breeds, uses and comprise, all  
44 sexes and ages, except for foals. Clinically, the disease is characterized by digital extensor  
45 dysfunction, primarily affecting the pelvic limbs resulting in knuckling in the  
46 metatarsophalangeal joints (1, 3, 4) (Fig. 1). In mild cases, knuckling ~~occurs~~~~is presented~~ only  
47 rarely unless provoked by e.g. tight circling or sudden stop from trot. Apart from these  
48 manipulations of movement, digital extensor dysfunction may be exacerbatedd with sudden  
49 distress, which requires careful handling during clinical examination of more severe cases (4).  
50 Horses with AEP do not appear ataxic. The horses are otherwise alert, responsive with normal  
51 appetite and clinical variables are within normal limits. There have been no significant  
52 abnormalities on laboratory analysis of blood or cerebrospinal fluid when examined (1, 2).

53 The clinical disease course is highly variable. In the most severe and acute cases, horses  
54 suddenly knuckle and ~~stand~~~~rest~~ on the dorsal metatarsophalangeal region without being able  
55 to correct the abnormal limb position for seconds to minute(s). Such cases are often unable to  
56 get up from recumbency, even with assistance. In less severe and more prolonged disease  
57 courses, horses knuckle intermittently for months before they either improve slowly, or  
58 suddenly deteriorate and become recumbent. Horses that remain able to rise and stand with or

59 without support mostly recover completely with long convalescence. Intermittent knuckling  
60 ~~has,ve~~ however, been observed for up to 17 months after onset, with a median duration of  
61 clinical signs of 4.4 months (4). Case fatality rates vary ~~in~~between outbreaks and range from  
62 29% to 53% (1, 4, 8).

63 Typically, AEP affects more than one, but not all horses in a stable and has a seasonal pattern  
64 with most cases appearing during winter and springtime, indicating an environmental trigger  
65 (1, 4, 5). A ~~specific~~certain aetiology has not been associated to AEP despite extensive studies,  
66 but almost all cases have been fed wrapped forage, indicating an alimentary risk factor of  
67 unclear nature (1, 4). However, analysis of the hygienic, botanical, chemical and  
68 microbiological composition of wrapped forage have so far failed to identify a disease causing  
69 agent (unpublished data) (4).

70 Despite ~~the high disease prevalence~~the relative large number of cases, the sparse availability  
71 of fresh material for peripheral nerve studies has hitherto limited the possibilities to clarify the  
72 pathobiology of AEP from the tissue perspective. Post-mortem examination of the nervous  
73 system of 22 horses diagnosed with AEP in Norway (1) and a number of horses in Sweden  
74 (unpublished) indicated a polyneuropathy, but obtained tissues did not allow for further  
75 classification. The only in depth investigation reported was from ~~in~~one single horse from  
76 Finland and it revealed schwannopathic features and nerve-- fibre -invasive inflammation (3).  
77 Whether these lesions are characteristic of AEP remains yet unknown, in particular because~~as~~  
78 this horse also was ataxic (3), which is unusual for the majority of AEP cases (1, 4). Hence, it  
79 was the aim of this study to clarify peripheral nerve and muscle changes of an extended series  
80 of AEP horses presenting with classical clinical signs, in order to approach the underlying  
81 pathological mechanisms and aetiological triggers.

## 82 **2. Material & Methods**

## 83 2.1 Included horses

84 Horses were recruited from outbreaks of AEP reported to the Equine Clinic, Norwegian  
85 University of Life Sciences (NMBU) or National Veterinary Institute, Sweden, between 2005  
86 and 2014. In accordance with former published diagnostic algorithms (1, 4), inclusion criteria  
87 were a clinical history of repeated bilateral pelvic limb knuckling without ~~overt~~ signs of a  
88 ~~central nervous system disease~~involvement of the nervous system of the head or other  
89 abnormal clinical signs. Exclusion criteria included: 1) primary musculoskeletal disorders  
90 affecting the metatarsophalangeal joint, 2) neuromuscular junction disorders, 3) spinal ataxia  
91 ~~or indication of any other central nervous system (CNS) involvement~~ or 4) primary muscle  
92 disease and other causes of non-neurologic pelvic limb weakness~~paralysis~~. All horse owners  
93 consented for the results to be included in this study.

94 Based on neurological examination by authors (SHO, GG,12 cases) , ~~and videos and/or~~  
95 veterinary records from the neurological evaluation performed by local veterinarians with or  
96 without videos (four cases), the clinical severity of each case was graded at least two times; at  
97 onset and at time of sampling, some cases also in between. Severity were graded I-IV  
98 according to a semiquantitative grading system established earlier (1) (Table 1, video 1 and  
99 2). Biopsies and autopsies were performed for diagnostic reasons.

## 100 2.2 Sampling

101 In the cases that were euthanized on humane grounds due to deterioration or an uncertain  
102 prognosis, samples were taken at autopsy. Fascicular nerve specimens were taken from one or  
103 more of the following sites: recurrent laryngeal nerve, median nerve, lateral digital palmar  
104 nerve, femoral nerve, sciatic nerve, tibial nerve, common and superficial peroneal nerve and  
105 lateral digital plantar nerve (supplementary item ). If possible, nerves were collected from

106 both sides of the body, particularly in the case of the recurrent laryngeal nerves-. Specimens  
107 from spinal nerve roots were resected after extensive laminectomy.

108 Biopsies from appendicular muscles including triceps, extensor carpi radialis, quadriceps  
109 (vastus lateralis), tibialis cranialis and/or extensor digitalis longus and gluteal muscles were  
110 harvested, and specimens were immediately shipped overnight to the laboratories for  
111 processing. Cases that were recovering had at least one skeletal muscle biopsy taken.

## 112 *2.3 Histological processing*

### 113 *2.3.1 Nerve processing*

114 All nerve samples underwent the routine biopsy protocol established at the Neuropathology  
115 Laboratory, Ludwig-Maximilians University of Munich (LMU), Germany. It includes: 1)  
116 paraffin embedding for assessment of epineurial, interstitial and vascular abnormalities, 2)  
117 semithin sections, 3) nerve fibre teasing (NFT) for assessment of myelinated nerve fibre  
118 characteristics and 4) transmission electron microscopy (TEM) for identification of  
119 subcellular changes and unmyelinated fibre pathologies.

120 Paraffin embedding was preceded by whole-trunk immersion in 10% neutral buffered  
121 formalin for at least 24 hours, after which the fascicles were trimmed and underwent an  
122 ascending ethanol series and immersion in liquid paraffin using an automatic tissue processor  
123 (Hypercenter®, Shandon Inc.). Sections were cut at 3 µm and subsequently stained by  
124 haematoxylin-eosin (HE), Goldner's trichrome stain (GTS), and picrosirius red-alcian blue  
125 staining (PICRAB) (9). Upon paraffin embedding, transverse sections of the spinal cord  
126 samples were performed and stained with HE and trichrome to evaluate neural versus  
127 interstitial and vascular changes.

128 For semithin histology, NFT and TEM, large fascicles were gently separated and immersed in  
129 2.5% glutaraldehyde in 0.1M Soerensen's phosphate buffer for 1-2 hours. Thereafter they

130 were incubated in washing buffer. A series of fascicular full trunk samples of 2 mm length  
131 were obtained using a razor blade on the proximal and distal edges of the specimens. These  
132 pieces were subjected for transverse and longitudinal sectioning. They were post-fixed in 2%  
133 osmium tetroxide, dehydrated by an ascending ethanol series and embedded in epoxy resin.  
134 Semithin sections were processed at 0.5 µm thickness and stained by p-phenylene diamine  
135 and modified Richardson's stain, using azure II methylene blue and safranin-O (10). On  
136 semithin scout sections, candidate areas were identified for TEM, trimmed, sectioned at 50  
137 nm, mounted on copper grids and contrasted with lead citrate and uranyl-acetate. Ultrathin  
138 sections were stored in an exsiccator until ultrastructural examination. Trimmed fascicles also  
139 were impregnated in 2% osmium tetroxide, washed in phosphate buffer before undergoing  
140 NFT after immersion in glycerol with and without haematoxylin counterstaining (10).

141 The neuromorphological investigation employed standard algorithms for peripheral nerve  
142 diagnostics (11) and analyzed samples from neurological horses in comparison to age- and  
143 breed-group matched non-neurologic controls (74 horses; 46 female/28 male, 6 weeks to 28  
144 years) available through the archive of the Neuropathology Laboratory, LMU, Germany.

145 Checklist for myelinated nerve fibre evaluation included abnormalities of Schwann cell  
146 nucleus and perikaryon, the presence of Schwann cell inclusions, the thickness and integrity  
147 of compacted and uncompact myelin, the width and content of the nodal gap, the axonal  
148 diameters, the density, distribution and morphology of the axonal cytoskeleton and  
149 axoplasmic organellae, the frequency and spatial distribution of the axon-Schwann cell  
150 network (ASN), the appearance of the inner and outer endoneurial sheath and the presence of  
151 nodal gap cells, fibre-adhesive and fibre-invasive immune cells. The appearance of  
152 unmyelinated nerve fibres, including C-fibre axons and their ensheathing Remak cells and  
153 basilar laminae as well as the presence of collagen pockets and empty Schwann cell subunits  
154 were evaluated at ultrastructural level. All histological investigations were carried out at a

155 Zeiss Axiophot® equipped with a CCD camera with magnifications ranging from x125 to  
156 x1000. TEM was performed at a Zeiss EM10®, at 80kV, with a magnification of x1500 to  
157 x100.000.

### 158 *2.3.2 Immunohistology of nerves*

159 Upon histological evaluation, immunohistochemical labelling techniques were employed for  
160 assessment of endoneurial immune cell infiltrates and endoplasmic reticulum stress.

161 The following markers were applied for immune cell phenotyping: T-cell marker CD3  
162 (monoclonal mouse, clone F7.2.38, 1:200, Dakocytomation, Glostrup, Denmark), B-cell  
163 marker CD79a (monoclonal mouse, clone HM57, 1:500, Dakocytomation, Glostrup,  
164 Denmark), lysozyme (polyclonal rabbit, 1:200, Linaris, Freiburg, Germany) and MAC387  
165 (polyclonal rabbit antibody, 1:1000, Linaris, Freiburg, Germany) labelling histiocytes and  
166 macrophages. Detection of humoral factors was performed using antibodies directed at horse  
167 IgG (polyclonal rabbit, Linaris, 1:100, Freiburg, Germany). These markers were applied on  
168 deparaffinised sections and on selected teased fibres after fixation with 4% paraformaldehyde  
169 and treatment with 20M sucrose. Endoplasmic reticulum (ER) dysfunction was evaluated via  
170 the ER chaperone and signaling regulator GRP78/BiP.

171 Immunohistochemical procedures on sections employed antigen retrieval with microwave  
172 treatment in citrate buffer (20 min, pH 6.0, 800 W), overnight incubation with the primary  
173 antibodies at 4°C, avidin-biotin enhancer (ABC kit, Linaris, Freiburg, Germany) and a  
174 diaminobenzidine hydrochloride detection kit. Whole mount immunohistochemistry of teased  
175 fibres was conducted as single and double labelling study. Following microwave treatment,  
176 incubation with each primary antibody was carried out for 5 days at 37°C in a humid  
177 chamber. Immersion with the second primary antibody was preceded by LinBloc® (Linaris,



178 Freiburg, Germany) treatment. Histogreen® (Linaris, Freiburg, Germany) was used as second  
179 chromagen.

### 180 2.3.3 Muscle processing

181 Between one and four biopsies from different muscles were examined for individual horse  
182 ([supplementary item 1](#)). Samples were [immersed in liquid nitrogen and](#) processed to frozen  
183 and formalin fixed slides stained with HE, periodic acid Schiff (PAS) with and without  
184 diastase pretreatment and Masson`s trichrome techniques. In two cases [modified](#) Gomori  
185 [trichrome](#) and fibre typing [with adenosine triphosphatase \(ATPase\) and nicotinamide adenine](#)  
186 [dinucleotide \(NADH\) tetrazolium reductase staining](#) was also performed.

### 187 2.4 Data analysis

188 Nerve lesion scores (0-3) were obtained for myelinated fibre loss, actual demyelinating and  
189 axonal pathologies, Schwann cell changes and inflammatory features\_(12). Lesion occurrence  
190 and scores were compared in between acute ( $\leq 4$  weeks disease history) and chronic ( $\geq 8$  weeks  
191 disease history) cases using chi square /Fisher`s exact test and Mann Whitney test. The  
192 interdependence between nerve lesions and clinical grades was evaluated via Kendall-Tau  
193 test. P values  $\leq 0.05$  were accepted indicating significance.

## 194 3. Results

### 195 3.1 Demographics and management

196 Sixteen horses from Norway and Sweden were included in the study. Case horses were aged  
197 between 1 and 25 years (mean 10), represented all sexes and 9 different breeds (Table 2).  
198 Stabling included both small units with less than 10 horses and large stables with up to 80  
199 horses. Prevalence of AEP at farm level varied and ranged from 1 affected out of 50 horses to  
200 10 out of 14. All cases had been fed wrapped forage preceding the disease. Two cases (No. 1  
201 and 7) had been stabled in farms together with AEP cases earlier, but at that point without any

202 clinical signs of AEP. Horse No. 1 was ~~stabled together with exposed to~~ a single AEP horse a  
203 year before and was then, in the present study, ~~part of affected by~~ a large outbreak involving  
204 10 out of 14 stablemates. Horse No. 7 was stabled at a farm with several AEP affected horses  
205 four years prior to inclusion in the study, and at that time found ~~to be~~ neurologically  
206 ~~normal unaffected~~ by one of the authors (SHO). The horse thereafter changed stables and had  
207 no history of neurological deficits during the four years ~~that followed to come~~. She was then  
208 the only horse diagnosed with AEP at the farm.

### 209 3.2 Clinical course

210 ~~The included horses represented all four severity grades at onset of disease, see Table 2 and~~  
211 ~~Fig. 2 for details. The severity of clinical signs at onset of the disease was grade I in four~~  
212 ~~horses, grade II in six horses, grade III in four horses and grade IV in two horses (Table 2,~~  
213 ~~Fig. 2). Owners had elected euthanasia in 14 out of 16 case horses. The duration of the disease~~  
214 before sampling (observation time) was four weeks or less ~~and classified as acute~~ in six  
215 horses, ~~six and seven weeks respectively in two horses,~~ and more than eight weeks, ~~classified~~  
216 ~~as chronic.~~ in eight horses, ~~four of which more than a year~~ (Table 2). ~~Based on this, six horses~~  
217 ~~(No. 1-6) with clinical disease history of  $\leq 4$  weeks were classified as acute and eight horses~~  
218 ~~(No. 7-14) with  $\geq 8$  weeks duration, as chronic.~~ The two surviving horses with six and seven  
219 weeks observation time (No. 15, 16) had only muscle biopsies taken and were not included in  
220 the statistical analysis.

221 ~~In five horses neurological deterioration (n=3 grade III to grade IV, n=2 grade I to grade IV)~~  
222 ~~occurred over 10 days to 4 months (Fig. 2). In three horses with grade I (n=2) or grade III~~  
223 ~~(n=1) neurological deficits remained constant whereas in the remaining eight horses remission~~  
224 ~~in clinical signs was observed. In six of the eight horses, recovery was incomplete (initial~~  
225 ~~grade II, grade I at time of euthanasia). A neurological deterioration was seen in five horses~~  
226 ~~during an observational time of ten days to four months. Three of these horses progressed~~

227 ~~from grade III to IV, and two deteriorated from grade I on first examination, to grade IV at~~  
228 ~~time of euthanasia (Fig. 2). Neurological deficits remained constant during the observation~~  
229 ~~period of seven days to two months in three horses (3/16), presenting with grade I (n=2) or~~  
230 ~~grade III (n=1). Remission of clinical signs was seen in 8/16 horses. Recovery was incomplete~~  
231 ~~in six horses which had showed grade II compromise at initial presentation, and grade I at~~  
232 ~~time of euthanasia (observational time of four months to two years).~~ Two surviving ponies  
233 improved from grade IV to grade I and grade III, respectively, within the 6-7 weeks that  
234 passed from clinical onset to biopsy. They made a complete recovery from clinical signs of  
235 AEP within six months following sampling, and remained free during the following years.

### 236 *3.3 Pathology*

#### 237 *3.3.1 Tissue availability*

238 In total, 105 nerve samples were collected from 14 horses that were subject to euthanasia. The  
239 samples originated from of up to 15 different nerve-sites from both sides of the body. From  
240 five horses, spinal nerve roots were resected. The samples contained one isolated dorsal root  
241 ganglion (DRG) (1/5), DRG plus postganglionic dorsal root and subganglionic ventral root  
242 (3/5) or not further specified fragments of non-ganglionic nerve roots (1/5). In depth  
243 evaluation of muscles and/or nerves was performed in all 14 euthanized horses (Table 2), in  
244 the two surviving case horses tissue diagnostics was limited to muscle biopsies. In addition,  
245 full autopsy was performed in four horses, according to respective consent of the owners.

#### 246 *3.3.2. Nerve pathology*

247 All 14 AEP cases showed significant and rather uniform peripheral nerve changes extending  
248 throughout all sampling sites, with minor random variations (Table 3). At stage of sampling,  
249 all nerves exhibited mild to moderate loss of myelinated nerve fibres (MF), with or without

250 large-fiber predominance (7 of each) (Fig. 3). Total MF drop-out appeared mildly more  
251 advanced in acute versus chronic cases ( $p=0.03$ , Table 3).

252 In all but one horse (Table 2 No. 7, a chronic case), the nerves showed axonopathic MF  
253 features. Axonal atrophy with subsequent internodal myelin sheath crenation, inner and out-  
254 folded myelin loops and concentric myelin sheath adjustment was most prevalent, affecting  
255 13/14 horses. More conspicuously, axonal swelling was noted due to abnormal axoplasmic  
256 aggregation of mitochondrial, multivesicular and dense bodies plus proliferation of axon-  
257 Schwann cell network in three acute (No. 2, 3, 6) and one chronic case (No. 9). Finally, four  
258 acute (all but No. 1 and 4) and five chronic cases (No. 8, 10-12, 14) presented with various  
259 stages of Wallerian degeneration. Amongst axonal changes, acute cases showed higher  
260 degrees of axonal atrophy ( $P<0.02$ ; Table 3) if compared to chronic presentations. No  
261 significant differences were seen regarding occurrence and stage of Wallerian degeneration.  
262 There was however an an weak interdependence between Wallerian degeneration and severity  
263 degree of clinical signs in the acute cases ( $P=0.02$ ,  $r=0.8022$ ), with more pronounced  
264 Wallerian degeneration seen in the most severe cases.

265 Myelin sheath changes were evident throughout acute and chronic cases (Table 3, Fig. 3),  
266 including the single case lacking axonal pathologies (No. 7). With exception of horse No. 12,  
267 demyelinating features affected large fibre types only. These comprised interspersed or  
268 clustered demyelinated and hypomyelinated segments in all horses as well as paranodal  
269 demyelination with stepped remyelination and formation of pseudo- or hemi-nodes in two  
270 acute (No. 2, 6) and three chronic cases (No. 7, 9, 14) and dysmorphic paranodes in four acute  
271 (No. 1, 2, 5, 6) and two chronic cases (No. 12, 14).

272 Myelin sheath destruction was associated with fibre-adherent (12/14) (No. 1-11, 14) and even  
273 fibre-invasive (9/14) (No. 1-3, 5-7, 10, 11, 14) mononuclear round cells in a majority of cases  
274 (Table 3, Fig. 4). The degree of fibre-directed infiltrates in acute cases was statistically linked

275 to the severity degree of clinical signs ( $P=0.04$ ;  $r=0.83$ ), with more infiltrates seen in the most  
276 severe cases. All but one horse (13/14, exception No. 5) further presented with a diffuse  
277 lymphohistiocytic infiltration of the endoneurium that mainly expressed T-cell marker CD3  
278 and lysozyme followed by a few CD79a-positive B-lymphocytes. Investigation of teased  
279 whole mount fibres was consistent with very mild immunopositivity for IgG within the  
280 myelin spiral.

281 Dyscompaction of myelin was noted in one acute (No. 3) and four chronic AEP cases (No. 7,  
282 8, 12, 13) in terms of tomacula (No. 8, 12, 13), adaxonal and interlamellar ballooning (No. 3,  
283 7).

284 Severe hypertrophy of nearly all Schwann cell perikarya was observed in 12/14 AEP horses  
285 (all but No. 13 and 14), with higher scores for the acute cases ( $P=0.04$ , Table 3). All six acute  
286 and five chronic cases presented with highly conspicuous amorphic perinuclear Schwann cell  
287 inclusions (Fig. 5). The inclusions stained osmiophobic, pale-azurophilic and GRP78/BiP-  
288 positive, on immunohistochemistry. On electron microscopy, they resembled flocculent  
289 electron dense material suggestive of non-filamentous protein accumulation. The content  
290 appeared not to be bound by a membrane, but was rather indistinctly separated from the  
291 cytosol. Apparently independent of the clinical stage, all but two cases (No. 1 and 13) showed  
292 hyperplastic Schwann cells and supernumerary Schwann cell processes (“onion bulbs”)  
293 centered on demyelinated incompletely remyelinated fibres.

294 Insights from 2-15 sampling sites in 7/14 horses (No. 1, 4, 9, 10, 12, 13, 14) ruled out  
295 significant proximodistal gradients and asymmetric nerve affection with regards to axonal  
296 changes. This contrasts to proximal predominance of inflammatory features in one acute  
297 (No.3) and two chronic cases (No. 7, 11). Furthermore, in two horses with bilateral peroneal  
298 nerve sampling, Schwann cell inclusions were seen in one side only. Another single acute

299 case (No. 5) with four sites investigated, presented with the -peroneal nerve being most  
300 severely affected by all type of changes.

301 All three DRG (3/5) showed patchy increase of satellite cells and some Nageotte bodies in  
302 DRG. Lymphoplasmocytic aggregates were occasionally seen in all five animals. In three  
303 samples out of four containing distinctive dorsal and ventral roots, the inflammatory changes  
304 were more prominent in the dorsal roots.

### 305 3.3.3. Muscle pathology

306 A total of 24 muscle biopsies were sampled from 7 cases (supplementary item 1, Table 2, No.  
307 2, 3, 6, 7, 11, 15, 16). All samples showed similar changes, namely had occasional fibres with  
308 euchromatic peripheral nuclei, and degrees of very mild to moderate multifocal myofibre  
309 atrophy with mild small group atrophy and occasional anguloid fibres. Intramuscular axons  
310 were rarely observed and appeared normal. Overtly angular fibres were rare, however in four  
311 of the cases the changes may be significant enough to be due to mild denervation. Two cases  
312 showed marked atrophy of both fibre types. One of these had been recumbent for a significant  
313 amount of time and additionally showed occasional single fibre necrosis of hypertrophic  
314 fibres. In no samples was there evidence of arteritis, cellular infiltrate or apparent replacement  
315 of fibres with adipose or fibrous tissue.

316

## 317 4. Discussion

318 Although the total number of AEP affected horses is not very high, it is the most prevalent  
319 polyneuropathy in horses in a geographically restricted area. AEP is a highly prevalent  
320 emerging, but geographically restricted, polyneuropathy in horses that It presents uniformly  
321 presents with knuckling in the metatarsophalangeal joints due to extensor weakness/paresis or  
322 flexor-extensor incoordination. This study identified a high level of pathomorphological  
323 homogeneity amongst the multiple investigated nerves, biopsy sites and individuals

324 throughout the affected farms in Scandinavia. Very much like our first observation in nerves  
325 from a Finnish AEP affected horse, the cases from Norway and Sweden presented  
326 predominantly with a hitherto undetermined inclusion body schwannopathy and recurrent  
327 inflammatory demyelination. According to the lack of respective neurological and veterinary  
328 reports literature and our own laboratory files, comprising several thousand clinical cases since  
329 the 1980's, a similar bimodal neuropathy has not been recognized previously. In equids, the  
330 closest reported equivalent to AEP is a knuckling neuropathy described in three young horses  
331 from Japan (13, 14). Most of the resemblance herein refers to the clinical presentation,  
332 demyelinating-remyelinating features and some Wallerian degeneration seen predominantly  
333 in large myelinated fibers (13, 14). However, there is no reference in the Japanese case studies  
334 to Schwann cell changes and inflammatory features similar to what we see in AEP. In contrast  
335 to AEP, moreover, Japanese cases also demonstrated denervation of limb muscles. In Nordic  
336 horses affected by AEP, evidence of denervation was only subtle and inconsistent. Even the  
337 surviving horse that presented with disability grade III on sampling, showed disuse atrophy  
338 and paresis of the muscle due to demyelination rather than denervation. Hence, the dropout of  
339 large myelinated fibres in AEP nerves is supposed to result from a decay of Ia/Ib afferents  
340 rather than motor axons. Credence to this hypothesis is lent by the relative preservation of  
341 spinal ventral roots if compared to dorsal roots in a smaller series of cases (not shown).

342 Similar to the fibre dropout, schwannopathic features mainly were restricted to those cells  
343 enveloping large myelinated fibres. In contrast to the earlier case with aggregates seen in the  
344 rough endoplasmic reticulum (rER) (3), large cytoplasmic Schwann cell inclusions were not  
345 membrane bound at time of sampling. On the other hand, they consistently stained  
346 immunopositive for BiP/GRP78, indicating that the inclusions indeed may result from  
347 defective posttranslational protein processing, irrespective of rER membrane preservation.  
348 BiP/GRP78 belongs to the group of peptide-binding molecular chaperones that interact with

349 protein-folding intermediates to prevent protein aggregation by keeping it in a folding-  
350 competent state (15). Chaperones guarantee that only properly assembled and folded proteins  
351 are able to leave the rER, while unfolded or misfolded proteins will accumulate, awaiting  
352 proteosomal degradation. Several circumstances such as macromolecular crowding, oxidative  
353 stress, exposure to toxins, and aging may impair protein folding and/or affect rescue  
354 mechanisms such as ubiquitination/proteosomal activity and autophagy (16). Consequently,  
355 the triggers of AEP appears either to directly interfere with protein folding and rescue  
356 mechanisms or incite one of the named prerequisite disturbances. Even though a toxic  
357 principle is very likely, there is no poison known to us that is likely to reproduce exactly these  
358 changes. Misfolding of proteins and pathological aggregation in experimental settings also are  
359 known to enhance the immunogenicity of proteins explaining the autoimmune side effects of  
360 certain drugs and nanoparticles (17). Sporadic inclusion body myositis (sIBM) is a natural  
361 example of how misfolding and dysfunctional proteosomal pathways may lead to cellular  
362 autoimmune responses (16). Sporadic inclusion body myositis is the most common human  
363 myopathy presenting over the age of 40 years. Respective muscle fibre inclusions also stain  
364 positive for peptide-binding chaperones, disulfide isomerases and lectin chaperones, all of  
365 which individually document unfolding and/or misfolding of peptide chains and  
366 glycoproteins. Sporadic inclusion body myositis is an acquired immune-mediated myopathy,  
367 but the susceptibility to sIBM and progression of disease appear to segregate with certain  
368 HLA haplotypes (18, 19). The employed immune effector cascades recruit cytotoxic T cells  
369 and autoantibodies. That autoimmunity does not tell the whole story has been nicely  
370 demonstrated by the general failure of immunosuppressive treatment in sIBM (20). Even  
371 though the comparison is tempting, AEP epidemiology does not indicate an MHC haplotype  
372 association (4). It also is not restricted to a certain age segment but affects all breeds, ages and  
373 sexes non-selectively. Moreover, in contrast to sIBM, there is no exact match between the  
374 extent of histopathological damage and clinical disability. This renders an unseen factor



375 likely, one that interferes with nerve fibresensory function at the level of impulse conduction  
376 or neurotransmission. Hence, even if myelination is maintained, affected Schwann cells may  
377 be partially dysfunctional. Factors may e.g. interfere with transmembranous transport and  
378 detoxification at paranodes and Schmidt-Lanterman clefts (21). Alternatively, nerve  
379 conduction may be impaired at the level of nodal axolemma or within the dorsal root ganglia  
380 (DRG). Preliminary DRG investigations indeed revealed occasional degeneration of sensory  
381 neurons in single AEP cases. Moreover, in the context of autoimmunity, humoral factors that  
382 not necessarily lead to cell-mediated myelinotoxicity require consideration. Such soluble  
383 factors are involved in cases of Guillain-Barré syndrome (GBS) in people (22). Axonal  
384 conduction block can be caused by antibodies neutralizing transient voltage-gated Na<sup>+</sup>  
385 channels clustered at the node of Ranvier (23). Immunomodulatory treatment may remove  
386 antibodies or other factors interfering with Na<sup>+</sup> channel function improving nerve function  
387 ahead of possible structural restoration (22). Weak immunopositivity for intralesional  
388 immunoglobulins and the lack of correlation between the nerve fiber damage and the clinical  
389 impairment, render humoral immune mechanisms in AEP possible. Clarification as to whether  
390 these comprise anti-ganglioside antibodies as in GBS (24) awaits the availability of species  
391 specific serological tests for neural autoantibodies.

392 Peripheral nerve lesions in AEP cases are far more widespread than the clinical picture would  
393 suggest. This for example is evident in the recurrent laryngeal nerve, the longest peripheral  
394 nerve in equids, where the observed pathological lesions would be expected to compromise  
395 laryngeal function causing stridor. However, this has neither been observed clinically by  
396 roaring -nor has endoscopy performed in some AEP affected horses shown any laryngeal  
397 paresis. A slap-test (25) has been performed in most cases examined by the authors, but only  
398 rarely have a decreased leftsided reflex been noted (4). Mild symmetrical laryngeal  
399 hemiplegia could however go unnoticed if the horse is not exercised.

400 Investigation of nerve ~~samples~~biopsies allows for a specific AEP diagnosis and exclusion of  
401 relevant differential diagnoses, but it does not reflect the extent of dysfunction nor the clinical  
402 outcome. A more stringent evaluation of the neurophysiological impact of AEP pathology  
403 would require electrodiagnostics. In humans and small animals, electrophysiological  
404 investigations, rather than nerve biopsy, provide important determinants for peripheral nerve  
405 diagnosis as in the clinical work-up of GBS (22, 26). In horses, nerve conduction studies  
406 ~~require~~implicate general anesthesia or deep sedation, both of which relaxes the horse to a  
407 point where knuckling is easily induced ~~may worsen the clinical signs in AEP~~ and thus were  
408 declined by the owners. Diagnosis of mild and early AEP can therefore be challenging since it  
409 purely depends on observation of knuckling, which may happen intermittently and easily be  
410 missed by the owner and veterinarian. Thereby, estimation of disease duration can be  
411 underestimated, unless the animals were in daily use at disease onset, as in the present study.  
412 Neuropathies in humans are generally classified as acute if the time from onset to peak of  
413 signs is less than four weeks (22, 26, 27), while a clinical course over more than eight weeks  
414 is considered chronic (28, 29). Although not fully comparable since euthanasia ended the  
415 clinical course, we concluded that the six horses that were euthanized within four weeks were  
416 clinically in the acute phase of the disease. At odds with the short clinical disease-history  
417 however, histopathology featured chronic changes mainly such as onion bulbs. This  
418 corresponds to the acute onset seen in up to 16% of human patients diagnosed with chronic  
419 inflammatory demyelinating polyneuropathy (30, 31) and sporadically described in animals  
420 (32). As lesions progress and maybe converge, secondary features such as loss of fibres,  
421 secondary type of Wallerian degeneration, may mask the primary mode of lesion. The lag  
422 between induction and clinical manifestation of AEP further compromises the retrospective  
423 analysis of exposure to environmental factors such as feed, toxins and infectious pathogens.

424 The acute cases comprised the clinically most severely affected horses; five out of six were  
425 grade III or IV at the time of euthanasia. In the chronic group, only one horse was grade IV,  
426 the remaining seven were all grade I at the point of sampling. Interestingly, the significant  
427 difference between the two groups, with more extensive myelinated fiber loss and compound  
428 axonal pathologies in the acute group remained true also for the only grade I horse in the  
429 acute group and the grade IV case in the chronic group. The intercorrelation between fibre-  
430 directed infiltrates as well as Wallerian degeneration and clinical impairment in the acute  
431 group may very well be biased because of few horses included and only one mildly affected  
432 horse in this group. There was no correlation when comparing severity grades and infiltrates  
433 in all cases, disregarding disease duration. As much as the clinical examination focuses on  
434 disability, the grade of clinical compromise does not necessarily predict the disease course or  
435 outcome, as demonstrated by the various severity degrees and disease duration in the included  
436 cases. Indeed, with dedicated owners and cooperative patients many horses will overcome the  
437 disease, independent of the grade on admission or the maximal score of disability during the  
438 observational period (4, 33). As long as the animals rise and are able to stand with or without  
439 assistance every 24 hours (see supportive online material), full recovery may be possible. As  
440 nicely demonstrated in case No. 16, a show jumper pony, even horses with grade IV clinical  
441 signs may return to full performance levels. A transient and/or low exposure to AEP triggers  
442 may result in transient and mild clinical signs. The timeline of prodromal disease  
443 development however is unclear and **peripheral** nerves in horses that have fully recovered  
444 from AEP have yet to be investigated.

445 In conclusion, histopathological findings in AEP affected horses are strikingly similar despite  
446 variation in clinical severity and duration of disease at sampling, and comprise a re- and  
447 demyelinating, predominantly large fibre, neuropathy with conspicuous Schwann cell

448 inclusions. In contrast, muscle biopsies present with surprisingly mild changes. The aetiology  
449 remains unclear but an environmental toxin resembles the most likely pathogen.

450

451

452 Acknowledgments

453 We are grateful for horse owners and local veterinarians for their cooperation. Special thanks  
454 to to Dr Ebba Nilsson, Dr Karin Bernodt and Dr Erika Karlstam, National Veterinary  
455 Institute, and Dr Anders Linder, Eurofins Food/Agro, for autopsies and sampling in Sweden.  
456 The staff at the Department of Pathology, NMBU, is likewise thanked for autopsies  
457 performed in Norway. This study was funded by the Swedish-Norwegian Foundation for  
458 Equine Research, Grants no. V07-47001 and H14-47014 and Research Council of Norway  
459 Grant no. 248341 with contributions from the Norwegian Equine Center and the Agricultural  
460 Agreement Research Fund.

461

462 Reference List

463

464 1. Hanche-Olsen S, Teige J, Skaar I, Ihler CF. Polyneuropathy associated with forage sources in  
465 Norwegian horses. *J Vet Intern Med.* 2008;22(1):178-84.

466 2. Gustafsson K, Ronéus M. (Outbreaks of neurologic disorders in horses). *Sven Vet Tidning.*  
467 2000;52(5):253-9.

468 3. Hahn CN, Matiasek K, Syrja P, Jokinen TS, MacIntyre N, Tulamo RM. Polyneuropathy of  
469 Finnish horses characterised by inflammatory demyelination and intracisternal Schwann cell  
470 inclusions. *Equine Vet J.* 2008;40(3):231-6.

471 4. Gröndahl G, Hanche-Olsen S, Bröjer J, Ihler CF, Jäderlund KH, Egenvall A. Acquired equine  
472 polyneuropathy in Norway and Sweden: a clinical and epidemiological study. *Equine Vet J*  
473 *Suppl.* 2012(43):36-44.

474 5. Wolff C, Egenvall A, Hanche-Olsen S, Gröndahl G. Spatial and temporal distribution of  
475 incidence of acquired equine polyneuropathy in Norway and Sweden, 1995-2012. *BMC Vet*  
476 *Res.* 2014;10:265.

- 477 6. Telama H, Alho J, Virtala A-M, Tulamo R-M. Acquired equine polyneuropathy- a review and  
478 an account of Finnish outbreaks. *Suomen Eläinlääkärilehti*. 2011;117(5):301-8.
- 479 7. Hanche-Olsen S. Acquired equine polyneuropathy - clinical, pathological and epidemiological  
480 aspects [Philosophiae Doctor]. Oslo, Norway: Norwegian University of Life Sciences; 2017.
- 481 8. Fjordbakk CT, Strand E, Hanche-Olsen S. Surgical and conservative management of bilateral  
482 dynamic laryngeal collapse associated with poll flexion in harness race horses. *Vet Surg*.  
483 2008;37(6):501-7.
- 484 9. Kaemmer D, Bozkurt A, Otto J, Junge K, Klink C, Weis J, et al. Evaluation of tissue  
485 components in the peripheral nervous system using Sirius red staining and  
486 immunohistochemistry: a comparative study (human, pig, rat). *J Neurosci Methods*.  
487 2010;190(1):112-6.
- 488 10. Wieczorek LA. Nerve teasing as a diagnostic aid in detection of peripheral neuropathies:  
489 methodology and interpretation [Dissertation]. Munich: Ludwig-Maximilians-University;  
490 2002.
- 491 11. Gross S, Fischer A, Rosati M, Matiasek L, Corlazzoli D, Cappello R, et al. Nodoparanodopathy, internodopathy and cleftopathy: Target-based reclassification of Guillain-Barre-like immune-mediated polyradiculoneuropathies in dogs and cats. *Neuromuscul Disord*. 2016;26(12):825-36.
- 495 12. Pamphlett R, Sjarif A. Is quantitation necessary for assessment of sural nerve biopsies? *Muscle Nerve*. 2003;27(5):562-9.
- 497 13. Furuoka H, Mizushima M, Miyazawa K, Matsui T. Idiopathic peripheral neuropathy in a horse with knuckling. *Acta Neuropathol*. 1994;88(4):389-93.
- 499 14. Furuoka H, Okamoto R, Kitayama S, Asou S, Matsui T, Miyahara K. Idiopathic peripheral neuropathy in the horse with knuckling: muscle and nerve lesions in additional cases. *Acta Neuropathol*. 1998;96(4):431-7.
- 502 15. Chambers JE, Marciniak SJ. Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 2. Protein misfolding and ER stress. *Am J Physiol Cell Physiol*. 2014;307(8):C657-70.
- 505 16. Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. *Am J Pathol*. 2004;164(1):1-7.
- 507 17. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. *J Immunotoxicol*. 2014;11(2):99-109.
- 509 18. Mastaglia FL. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. *Acta Myol*. 2009;28(2):66-71.
- 511 19. Needham M, James I, Corbett A, Day T, Christiansen F, Phillips B, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. *J Neurol Neurosurg Psychiatry*. 2008;79(9):1056-60.
- 514 20. Gang Q, Bettencourt C, Machado P, Hanna MG, Houlden H. Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. *Orphanet J Rare Dis*. 2014;9:88.
- 516 21. Scherer SS, Deschênes SM, Xu YT, Grinspan JB, Fischbeck KH, Paul DL. Connexin32 is a myelin-related protein in the PNS and CNS. *J Neurosci*. 1995;15(12):8281-94.

- 518 22. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barre syndrome: an update. *J Clin Neurosci.*  
519 2009;16(6):733-41.
- 520 23. Weber F, Rüdell R, Aulkemeyer P, Brinkmeier H. Anti-GM1 antibodies can block neuronal  
521 voltage-gated sodium channels. *Muscle Nerve.* 2000;23(9):1414-20.
- 522 24. Dilley A, Gregson NA, Hadden RD, Smith KJ. Effects on axonal conduction of anti-  
523 ganglioside sera and sera from patients with Guillain-Barre syndrome. *J Neuroimmunol.*  
524 2003;139(1-2):133-40.
- 525 25. Greet TR, Jeffcott LB, Whitwell KE, Cook WR. The slap test for laryngeal adductory function  
526 in horses with suspected cervical spinal cord damage. *Equine Vet J.* 1980;12(3):127-31.
- 527 26. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre  
528 syndrome. *Ann Neurol.* 1990;27 Suppl:S21-4.
- 529 27. Van der Meché FG, Van Doorn PA, Meulstee J, Jennekens FG. Diagnostic and classification  
530 criteria for the Guillain-Barre syndrome. *Eur Neurol.* 2001;45(3):133-9.
- 531 28. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy  
532 (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology  
533 AIDS Task Force. *Neurology.* 1991;41(5):617-8.
- 534 29. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating  
535 polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic  
536 criteria. *Arch Neurol.* 1989;46(8):878-84.
- 537 30. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating  
538 polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. *Brain.*  
539 1987;110 ( Pt 6):1617-30.
- 540 31. Trojaborg W. Acute and chronic neuropathies: new aspects of Guillain-Barre syndrome and  
541 chronic inflammatory demyelinating polyneuropathy, an overview and an update.  
542 *Electroencephalogr Clin Neurophysiol.* 1998;107(5):303-16.
- 543 32. Molin J, Márquez M, Raurell X, Matiasek K, Ferrer I, Pumarola M. Acute clinical onset  
544 chronic inflammatory demyelinating polyneuropathy in a dog. *Muscle Nerve.* 2011;44(3):441-  
545 4.
- 546 33. Hanche-Olsen S, Kielland C, Ihler CF, Hultin Jaderlund K. Long-term follow-up of  
547 Norwegian horses affected with acquired equine polyneuropathy. *Equine Vet J.* 2017.
- 548